Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate AnaptysBio Inc before investing.

In this article, we go over a few key elements for understanding AnaptysBio Inc’s stock price such as:

• AnaptysBio Inc’s current stock price and volume
• Why AnaptysBio Inc’s stock price changed recently
• Upgrades and downgrades for ANAB from analysts
• ANAB’s stock price momentum as measured by its relative strength

About AnaptysBio Inc (ANAB)

Before we jump into AnaptysBio Inc’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

AnaptysBio, Inc. is a clinical-stage biotechnology company that delivers immunology therapeutics. It is focused on developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases. Its product candidate pipeline includes Rosnilimab, which is designed to suppress aberrant T cell driven inflammation by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; ANB032, which is designed to augment BTLA signaling that is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation; ANB033, which targets CD122, the common beta subunit shared by the IL-15 and IL-2 receptors; Imsidolimab, which inhibits the interleukin-36 receptor (IL-36R) and is developed for the treatment of generalized pustular psoriasis (GPP), and Etokimab, which inhibits IL-33 function and acts upstream of key cell types involved in atopy and the subsequent release of Th2 cytokines.

Want to learn more about AnaptysBio Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about AnaptysBio Inc.

AnaptysBio Inc’s Stock Price as of Market Close

As of December 05, 2023, 4:00 PM, CST, AnaptysBio Inc’s stock price was $16.24.

AnaptysBio Inc is up 4.17% from its previous closing price of $15.59.

During the last market session, AnaptysBio Inc’s stock traded between $14.70 and $15.60. Currently, there are 26.55 million shares of AnaptysBio Inc stock available for purchase.

Unfortunately, AnaptysBio Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

AnaptysBio Inc Stock Price History

AnaptysBio Inc’s (ANAB) price is currently up 14.85% so far this month.

During the month of December, AnaptysBio Inc’s stock price has reached a high of $16.37 and a low of $13.96.

Over the last year, AnaptysBio Inc has hit prices as high as $32.44 and as low as $13.36. Year to date, AnaptysBio Inc’s stock is down 53.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused AnaptysBio Inc Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 04, 2023, there was 1 analyst who downgraded AnaptysBio Inc’s stock and 4 analysts who upgraded over the last month.

Additionally, you'll want to evaluate AnaptysBio Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on AnaptysBio Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

AnaptysBio Inc’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about AnaptysBio Inc (ANAB) by visiting AAII Stock Evaluator.

Relative Price Strength of AnaptysBio Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 04, 2023, AnaptysBio Inc has a weighted four-quarter relative price strength of -16.59%, which translates to a Momentum Score of 21 and is considered to be Weak.

Want to learn more about how AnaptysBio Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

AnaptysBio Inc Stock Price: Bottom Line

As of December 5, 2023, AnaptysBio Inc’s stock price is $16.24, which is up 4.17% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like AnaptysBio Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.